Core Viewpoint - The article discusses the increasing interest among Silicon Valley tech executives in genetic testing for embryos, particularly for traits like intelligence and disease risk, reflecting a growing trend in reproductive technology and ethical concerns surrounding it [3][10]. Group 1: Genetic Testing Services - Venture capitalists and tech executives are investing in companies that offer embryo genetic testing services, with some willing to pay up to $50,000 for such services [4][8]. - Startups like Genomic Prediction and Nucleus Genomics provide embryo screening for traits such as intelligence, with costs ranging from $2,500 to $50,000 per embryo [7][8]. - The fertility tech sector has seen significant investment, with approximately $400 million raised annually from 2021 to 2023 [8]. Group 2: Ethical and Legal Concerns - The practice of embryo genetic testing raises ethical questions regarding its reliability, legality, and moral implications [10][12]. - Critics argue that the algorithms used for scoring traits are often opaque, leading to potential misinformed health choices by consumers [11]. - While embryo screening is legal in the U.S., it faces strict prohibitions in countries like Germany, the UK, and Italy [12]. Group 3: Societal Implications - The obsession with intelligence scores reflects a belief in meritocracy among Silicon Valley elites, who may view genetic advantages as a means to ensure their children's success [13]. - Concerns are raised about the normalization of concepts like "superior" and "inferior" genes, which could reinforce social inequalities based on biological determinism [13][14].